41234-43-9

Basic information

• Product Name: ethyl 1,2,3,4-tetrahydroisoquinoline-3-carboxylate
• Synonyms: ethyl 1,2,3,4-tetrahydroisoquinoline-3-carboxylate;1,2,3,4-Tetrahydro-3-isoquinolinecarboxylic acid ethyl ester;3-Isoquinolinecarboxylic acid, 1,2,3,4-tetrahydro-, ethyl ester;1,2,3,4-tetrahydro-3-Isoquinoline carbocylic acid ethyl ester;ethyl 1,2,3,4-tetrahydroisoquinoline-3-(S)-carboxylate
• CAS NO: 41234-43-9
• Molecular Formula: C₁₂H₁₅NO₂
• Molecular Weight: 205.253
• EINECS: 255-273-0
• Mol File: 41234-43-9.mol
• Article Data: 5

Chemical Properties

• Melting Point: 204℃
• Boiling Point: 313.2°Cat760mmHg
• Flash Point: 143.2°C
• Appearance: /Solid
• Density: 1.101g/cm³
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: ethyl 1,2,3,4-tetrahydroisoquinoline-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 1,2,3,4-tetrahydroisoquinoline-3-carboxylate(41234-43-9)
• EPA Substance Registry System: ethyl 1,2,3,4-tetrahydroisoquinoline-3-carboxylate(41234-43-9)

Safety Data

• Hazardous Substances Data: 41234-43-9(Hazardous Substances Data)

Usage

Description

Ethyl 1,2,3,4-tetrahydroisoquinoline-3-carboxylate is an organic compound that serves as a crucial synthetic intermediate in the pharmaceutical industry. It is characterized by its unique chemical structure, which allows for the development of various therapeutic agents.

Uses

Used in Pharmaceutical Industry:
Ethyl 1,2,3,4-tetrahydroisoquinoline-3-carboxylate is used as a synthetic intermediate for the preparation of quinapril derivatives. These derivatives act as bradykinin B2 receptor antagonists, which are essential in the treatment of hypertension and other cardiovascular conditions.
Additionally, ethyl 1,2,3,4-tetrahydroisoquinoline-3-carboxylate is used to synthesize quinolizidinone carboxylic acid, which serves as a selective M1 allosteric modulator. This modulator has potential applications in the treatment of cognitive impairments and other neurological disorders.

Upstream product

• 64-17-5 ethanol 
• 67123-97-1 (R,S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid 

Downstream Products

• 74163-81-8 L-Tic-OH 
• 1254944-66-5 ethyl 2-(5-(methylthio)thiophene-2-carbonyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate 
• 1380547-82-9 3-ethyl 2-(3-(trifluoromethyl)phenyl) 3,4-dihydroisoquinoline-2,3(1H)-dicarboxylate 
• 1262842-13-6 C₁₉H₂₁NO₄S 
• 1380547-84-1 3-ethyl 2-phenyl 3,4-dihydroisoquinoline-2,3(1H)-dicarboxylate 
• 101195-64-6 ethyl 2-(phenylcarbamoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate 
• 1380547-77-2 C₁₉H₁₈ClNO₃ 
• 1380547-80-7 C₁₈H₁₈BrNO₄S 
• 1380548-02-6 C₃₁H₃₁NO₃ 
• 1380547-98-7 (3-(([1,1'-biphenyl]-4-yloxy)methyl)-3,4-dihydroisoquinolin-2(1H)-yl)(naphthalen-1-yl)methanone 
• 1380547-97-6 C₂₇H₂₂FNO₂ 
• 1380547-96-5 C₂₈H₂₆N₂O 
• 1380547-95-4 C₂₉H₂₆N₂O₃ 
• 1380547-94-3 C₂₇H₂₄N₂O₃S 

Relevant articles and documents

NATURAL KILLER CELLS

This invention relates to Natural Killer (NK) cell populations, to methods of producing the same and therapeutic applications thereof. More specifically, the invention relates to the expansion of IMK cells by increasing the expression of specific transcription factors associated with NK cell production.

ANTIPARASITIC TERPENE ALKALOIDS

The present invention relates to novel terpene alkaloids and their use as antiparasitic agents. The present invention also relates to an antiparasitic agent which comprises a terpene alkaloid compound of this invention as an effective ingredient in an antiparasitic formulation. More particularly, the present invention relates to derivatives of the terpene alkaloid (1S,2R,4aS,5R,8R,8aR)-2-(acetyloxy)-8a-hydroxy-3,8-dimethyl-5-(1-methylethenyl)-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl (2S,3aR,9bR)-6-chloro-9b-hydroxy-5-methyl-1,2,3,3a,5,9b-hexahydropyrrolo[2,3-c][2,1]benzoxazine-2-carboxylate. Pharmaceutical compositions comprising the same are also disclosed.

BENZAMIDINE DERIVATIVES SUBSTITUTED BY CYCLIC AMINO ACID AND CYCLIC HYDROXY ACID DERIVATIVES AND THEIR USE AS ANTI-COAGULANTS

This invention is directed to benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives which are useful as anti-coagulants. This invention is also directed to pharmaceutical compositions containing the compounds of the invention, and methods of using the compounds to treat disease-states characterized by thrombotic activity.